Research programme: gap junction modulators - Zealand Pharma

Drug Profile

Research programme: gap junction modulators - Zealand Pharma

Alternative Names: ZP 1210

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Zealand Pharma
  • Developer Pfizer; Zealand Pharma
  • Class Small molecules
  • Mechanism of Action Gap junction modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders

Most Recent Events

  • 13 Apr 2016 Preclinical pharmacodynamics data released by Zealand Pharma
  • 15 Oct 2009 Wyeth has been acquired by Pfizer
  • 04 Sep 2009 Pharmacodynamics data from a preclinical investigation in arrhythmia presented at the 238th National Meeting of the American Chemical Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top